钠-葡萄糖协同转运蛋白2抑制剂的心血管获益机制探讨  

The mechanisms of sodium-glucose cotransporter 2 inhibitor in bringing cardiovascular benefits

作　　者：刘智杰 边宁[1] 潘贇 陈冬冬[1] LIU Zhijie;BIAN Ning;PAN Yun;CHEN Dongdong(Department of Cardiology,The First Affiliated Hospital of Ji'nan University,Guangzhou,510630,China)

机构地区：[1]暨南大学附属第一医院心内科,广州510630

出　　处：《临床心血管病杂志》2021年第12期1075-1079,共5页Journal of Clinical Cardiology

摘　　要：心血管疾病(CVD)和糖尿病在全世界范围内影响着人类的生命和健康,当两者共存时更是形成相互促进的恶性循环,进一步增加风险和病死率。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是一类新型口服降糖药,除了能降低血糖之外,还显示出了明显的心血管获益作用,然而具体的机制目前尚未明确。本文将查阅和学习近期相关文献,总结SGLT2抑制剂在心血管方面的研究进展,以探讨其对心血管获益的可能机制,旨在能够为SGLT2抑制剂在CVD中的进一步应用提供依据,以改善CVD患者的临床结局。Cardiovascular diseases(CVD)and diabetes mellitus pose a threat to human life and health worldwide.A vicious circle of mutual promotion will take shape to increase risk and mortality further when CVD is complicated with diabetes mellitus.As a new oral hypoglycemic agent,sodium-glucose cotransporter 2(SGLT2)inhibitor has shown significant cardiovascular benefits in addition to lowering blood glucose.However,the specific mechanism has not been elucidated presently.In order to provide a basis for the further application of SGLT2 inhibitor in CVD and to improve the clinical prognosis of such patients,this article would consult and study latest pertinent literature and summarize the recent advance of SGLT2 inhibitor in cardiovascular terms and explore the potential mechanisms of its cardiovascular benefits.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 心血管疾病 糖尿病 获益机制 

分 类 号：R54[医药卫生—心血管疾病]